<DOC>
	<DOCNO>NCT00003390</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness 6-hydroxymethylacylfulvene treating patient metastatic kidney cancer .</brief_summary>
	<brief_title>6-Hydroxymethylacylfulvene Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate efficacy 6-hydroxymethylacylfulvene ( HMAF ) patient metastatic renal cell carcinoma . II . Investigate safety HMAF give patient population . OUTLINE : Patients receive 6-hydroxymethylacylfulvene intravenously 5 minute every day 5 consecutive day . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Patients follow every 2 treatment course . PROJECTED ACCRUAL : Approximately 12-37 patient accrue study within 6-19 month .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Irofulven</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm renal cell carcinoma evidence metastatic disease Bidimensionally measurable disease No active brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Greater 3 month Hematopoietic : WBC least 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin within normal range ALT/AST great 2.5 time upper limit normal ( ULN ) Renal : Creatinine within 1.5 time ULN AND Creatinine clearance least 50 mL/min Other : Not pregnant lactate Fertile patient must use effective contraception No prior malignancy within 5 year low risk recurrence Must undergone potentially curative therapy prior malignancy PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since biological therapy recover Chemotherapy : No prior cytotoxic chemotherapy Endocrine therapy : At least 4 week since hormone therapy recover Radiotherapy : At least 4 week since radiotherapy Surgery : At least 4 week since major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2000</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>